Option chain shows key data for Kairos Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Kairos Pharma.

Kairos Pharma (AMEX:KAPA) Stock, Option Chain

KAIROS PHARMA LTD

Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Palantir,Technologies,Japan,Logo,,Tokyo,,Japan,2024,Sep.15

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

TNXP

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Wall Street

Equities

Eurozone

Commodities

CMTL

LODE

PHIO

SLRX

SVMH

WDFC

US Stocks Mixed; Nasdaq Down Over 1%

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AMIX

APTO

BENF

CARE

CETX

Envoy Medical, Inc. - Class A Common Stock

COCH

ESTC

INTU

KSCP

PROC

RDDT

RMSG

ROST

VRPX

XCUR

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

Kairos Pharma Ltd

Biotech

Events

Press Releases

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

GSIT

PRSO

QNTM

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Immuron Limited - American Depositary Shares

Immuron

Leap Therapeutics

Moleculin Biotech

Marker Therapeutics

MetaVia

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

PharmaCyte Biotech

SAB Biotherapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Synlogic

D. Boral Capital

EF Hutton

Comments

Kairos Pharma

Kairos Pharma (KAPA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga